- Jun 2015 — Nanjing FMK Pharmaceutical Technology Co., Ltd. established
- Dec 2015 — Brazil office opened
2015
- Jun 2017 — Strategic partnerships with Dr. Reddy’s and MSN; began API import registration and sales
- Nov 2017 — Invested in Tianchi Pharmaceutical and completed Series A financing
- Dec 2017 — Signed global blood-product strategy with Boya Biological
2017
- Jul 2018 — Jointly invested in Jiangxi Huabang Pharmaceutical with Conba Group
- Aug 2018 — UK office opened
- Nov 2018 — Austria office opened
2018
- Apr 2019 — Invested in Jiangsu Huanghe Pharmaceutical Sales (GSP-qualified)
- Oct 2019 — Won Brazil Ministry of Health IVIG annual tender
- Nov 2019 — Established Nanjing Baizheng Biological Pharmaceutical
2019
- Mar 2020 — Pharmacaredonated Remdesivir to Thailand’s Ministry of Public Health for treating severe COVID-19 patients.
- Apr 2020 — Pharmacare supplied Favipiravir Tablets to Thailand’s Ministry of Public Health for COVID-19 treatment.
- Dec 2020 — Became a renowned domestic exporter of blood products.
- 5th Anniversary of Company Establishment
2020
- Founded Zhongke Baizheng (Suzhou) Biopharmaceutical Co., Ltd.
2021
- Mar 2022 — Served as Council Member of CCCMHPIE
- Aug 2022 — Awarded “Nanjing Gazelle Enterprise”
2022
- Dec 2023 — Awarded "Nanjing Gazelle Enterprise"
- Became Council Member of CCCMHPIE
- Submitted the first biosimilar registration dossier to Brazil ANVISA
- Launched the first overseas Phase III clinical project
2023
- Dec 2024 —Established a European subsidiary to improve the global industrial layout
- Deployed high-value orphan drugs and obtained multiple global-righted products
- Deepened South American market cooperation and obtained official insulin supply qualification
- Core products were successfully included in China's national volume-based procurement for large-scale market application
2024
- Expanded the global product portfolio covering biosimilars and complex formulations
- Submitted the first registration application for complex injectables to the EU
- Established a joint venture with a leading local pharmaceutical enterprise in Brazil
- Founded a wholly-owned subsidiary in Hong Kong
- Founded a joint venture in Thailand
2025
